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Collision tumors are rare neoplasms displaying two distinct cell populations developing in juxtaposition to one another without
areas of intermingling. They are rare entities with only 63 cases described in English literature. Tumors encountered are gastric
adenocarcinomas colliding with lymphomas, gastrointestinal stromal tumors, squamous cell carcinomas, and neuroendocrine
tumors. Their cell origin is obsolete by the time of diagnosis. Different tumorigenesis theories have been suggested to explain
their behavior, yet none has managed to provide satisfactory explanation for all cases. Clinically they are indistinguishable from the
dominant tumor. Lack of data does not allow detailed assessment of their behavior yet they seem aggressive neoplasms with dismal
prognosis. The majority of cases have been diagnosed postoperatively during histologic examination of specimens. There are no
guidelines or concrete evidence to support best way of adjuvant or other types of treatment. However, these rare neoplasms might
help in unlocking secrets of cancer behavior including tumorigenesis, differentiation, and adhesion and thus clinicians should be
aware of their existence.
1. Introduction
Gastric collision tumors are neoplasms consisting of two
distinct cell populations, developing in juxtaposition to one
another, without areas of intermingling [1–6]. They are
rare tumors and are diagnosed only rarely preoperatively.
Literature is comprised of case reports and a few case series;
thus our knowledge on them is scattered. Their clinical
and pathological behavior remains largely unknown as do
appropriate diagnostic and therapeutic procedures.
Gastric collision tumors are usually comprised of an
epithelial and a sarcomatous element. They should be dif-
ferentiated from other entities like carcinosarcomas (a sin-
gle neoplasm exhibiting a carcinomatous and a sarcoma-
tous pattern), composite tumors (two different histological
patterns intermingling in a single tumor), or cancer-to-
cancer metastasis (carcinoma metastasizing to a different
carcinoma) [7]. Neoplasms with two distinct populations but
without a clear-cut interface between histological patterns
or a transition zone of mixed character in between should
be categorized as composite neoplasms rather than collision
tumors [2, 8].
The first gastric collision tumor was probably described
by Jernstrom and Murray in 1966 [9] and consisted of a
gastric carcinoid colliding with an adenocarcinoma. Since
then only 18 similar cases have been described in the literature
(Table 1). Other types of collision tumors are lymphomas
colliding with gastric adenocarcinomas (26 cases, Table 2),
gastrointestinal stromal tumors (GISTs) collidingwith gastric
adenocarcinomas (9 cases, Table 3), squamous cell carcino-
mas collidingwith gastric adenocarcinomas (7 cases, Table 4),
and a few other isolated cases. Each category presents unique
characteristics, different behavior, and probably different
origin mechanism.
In this review authors present the published experience
in gastric collision tumors. We study their clinical behavior
and appropriate diagnostic and therapeutic procedures and
review tumorigenesis theories.
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Table 1: Neuroendocrine carcinoma and gastric adenocarcinoma collision tumors.
Author Sex/age Gastric adenocarcinoma Nodes Follow-up Adjuvant treatment
Grossi and Lattes [39], 1956 M/74 N/A N/A 12m N/A
Parks [20], 1970 M/54 N/A NEC/GA (+) 3m (DOD) N/A
Yamashina and Flinner [40], 1985 M/50 Mixed NEC (+) N/A N/A
Yoshino et al. [37], 1987 F/63 WD N/A N/A N/A
Chodankar et al. [41], 1989 F/69 WD — N/A N/A
Morishita et al. [28], 1991 M/49 MD N/A N/A N/A
Corsi and Bosman [42], 1995 M/72 MD N/A N/A N/A
Fukui et al. [21], 2001 M/63 PD N/A N/A N/A
de Leval et al. [11], 2002 M/87 WD NEC (+) 1m (DOD) N/A
Olinici et al. [43], 2004 M/68 N/A N/A N/A N/A
Morishita et al. [44], 2005 F/84 MD GA (+) 33m N/A
Jayaraman et al. [45], 2005 M/48 MD N/A N/A N/A
Jang et al. [10], 2010 M/50 WD NEC (+) N/A N/A
Doggui et al. [12], 2008 M/55 N/A N/A 3m (DOD) Chemo
Mardi et al. [46], 2008 F/47 WD GA (+) N/A N/A
Mro´z et al. [8], 2009 M/56 PD GA (+) N/A N/A
Lee et al. [33], 2011 M/62 PD — N/A N/A
U¨nal et al. [35], 2013 F/51 MD GA (+) 5m (DOD) N/A
N/A: Not available.
WD: Well differentiated.
MD: Moderately differentiated.
PD: Poorly differentiated.
NEC: Neuroendocrine carcinoma.
GA: Gastric adenocarcinoma.
m: Months.
DOD: Dead of disease.
2. Materials and Methods
An electronic bibliographic search was conducted in Med-
line Embase, Cinahl, and Cochrane Library for studies on
gastric collision tumors. Terms used were “gastric collision
tumor,” “neuroendocrine tumor and adenocarcinoma,” “lym-
phoma and adenocarcinoma,” “squamous cell carcinoma and
adenocarcinoma,” and “gastrointestinal stromal tumor and
adenocarcinoma.” Results were hand-searched and selected
appropriately. Moreover, literature of selected articles was
further hand-searched for relevant publications. Only articles
in English were included in this analysis.
2.1. Neuroendocrine Carcinomas and Gastric Adenocarcino-
mas. To our knowledge, 18 cases of collision tumors between
neuroendocrine carcinomas and gastric adenocarcinomas
have been described to date, 14 in males and 4 in females
(Table 1). The mean age of the patients was 61 years (47–
84). The majority were nonfunctional carcinoids while large
cell endocrine carcinoma [10] and gastrinomas [11, 12] have
also been described.The latter were discovered during inves-
tigation for Zollinger-Ellison syndrome. Five of the gastric
adenocarcinomas were poorly differentiated, 5 moderately
differentiated, and 3 well differentiated. Most authors do not
refer to lymphnode status; however in 4 of the cases theywere
infiltrated by gastric adenocarcinoma, 3 by neuroendocrine
tumor and in one from collision-type tumor.
2.2. Lymphomas and Gastric Adenocarcinomas. Collision
between lymphoma and gastric adenocarcinoma is the most
common category with 26 cases described to date. Eighteen
were described in males and 8 in females. The mean age
was 60 years (42–80). The majority of cases were MALT
lymphomas.
Collision tumors between lymphomas and gastric adeno-
carcinomas present some interesting characteristics. Accord-
ing to Nishino et al. [13], lymphomas are usually larger than
gastric adenocarcinomas and gastric adenocarcinomas are
usually early and well differentiated; however, Nakamura
et al. [14] reported that lymphomas are usuallymucosaMALT
lymphomas and gastric adenocarcinomas have higher Ki67
index. Prognosis is usually determined by the adenocar-
cinoma component. Goteri et al. [6] stated that glandular
epithelium inside aMALT lymphomamight bemore prone to
neoplastic transformation due to continuous inflammation.
In total, of the published cases 9 were early gastric can-
cers and only 5 were advanced. Fourteen cases were well, 1
moderately, and 7 poorly differentiated. Eleven cases were
of intestinal type, 5 of diffuse, and only 1 signet-ring cell
carcinoma.
One case of collision between Hodgkin’s lymphoma and
Gastric adenocarcinoma has been also described [15]. This
case is of particular interest since Hodgkin’s lymphoma was
also found in the perigastric lymph nodes. Authors believe
that the lymphoma component metastasized to the stomach
where it collided with a gastric adenocarcinoma.
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Table 2: Lymphoma and gastric adenocarcinoma collision tumors.
Author Sex/age Lymphoma Gastricadenocarcinoma Nodes Follow-up Adjuvant treatment
Jernstrom and Murray [9], 1966 F/72 Lymphosarcoma WD, I L/GA (+) 10m Radiotherapy
Manier and Reyes [3], 1974 M/65 Histiocytic EGC, PD L (+) 24m Chemotherapy
M/72 Histiocytic EGC, PD L/GA (+) 1,5m (DOS) None
Planker et al. [47], 1984 M/65 Immunocytoma EGC, MD, I L (+) N/A Radiotherapy
Kasahara et al. [4], 1988 F/72 Small cleaved B cells WD (−) 48m N/A
Noda et al. [38], 1989 M/69 Large-cell type EGC, WD (−) 9m Chemotherapy
Wotherspoon and Isaacson [24], 1995
F/55 MALT WD, D GA (+) N/A N/A
F/55 MALT AGC, WD, I GA (+) N/A N/A
M/N/A MALT AGC, WD, I (−) N/A N/A
F/69 MALT AGC, WD, I L/GA (+) N/A N/A
Nishino et al. [13], 1996 M/71 Diffuse large cell WD (−) 120m Chemotherapy
Nakamura et al. [14], 1997
M/42 Immunoblastic EGC, PD, D (−) 91m None
M/47 Superficial MALT EGC, PD, D (−) 24m Chemotherapy
M/53 Superficial MALT EGC, WD, I (−) 67m (DOD) None
F/67 Superficial MALT EGC, WD, I (−) 31m (DOD) None
M/78 T cell, pleomorphic AGC, PD, D GA (+) 1m (DOS) None
Goteri et al. [6], 1997
M/51 MALT EGC, WD, I (−) 122m N/A
F/55 MALT EGC, PD, D (−) 33m N/A
M/80 MALT EGC, WD, I L (+) 12m N/A
M/57 MALT EGC, WD, I L (+) 10m (DOD) N/A
Suenaga et al. [23], 2003 M/73 MALT AGC, WD, I GA (+) 23m (DOD) N/A
Isaka et al. [48], 2007 F/63 MALT N/A N/A 2m (DOD) N/A
Bhattacharya et al. [29], 2012 M/55 NHL WD N/A N/A N/A
M/67 NHL N/A N/A N/A N/A
Yanagawa et al. [15], 2012 M/72 HL PD L (+) N/A N/A
George and Junaid [49], 2014 M/53 MALT SRC N/A 2m N/A
MALT: Mucosa associated lymphoid tissue.
NHL: Non-Hodgkin’s lymphoma.
HL: Hodgkin’s lymphoma.
WD: Well differentiated.
MD: Moderately differentiated.
PD: Poorly differentiated.
EGC: Early gastric cancer.
AGC: Advanced gastric cancer.
D: Diffuse.
I: Intestinal.
L: Lymphoma.
GA: Gastric adenocarcinoma.
SRC: Signet ring cell.
m: Months.
DOD: Dead of disease.
N/A: Not available.
2.3. Squamous Cell Carcinomas and Gastric Adenocarcino-
mas. Only 9 cases of collision between squamous cell car-
cinoma (SCC) and gastric adenocarcinoma have been
described to date. Most cases were located at the gastroe-
sophageal junction with SCC lying at the esophageal side and
adenocarcinoma at the gastric side. All patients were males
with mean age of 49 years (37–73). In a composite tumor
described by Dodge [2] an anaplastic carcinoma was at the
gastric side and adenocarcinoma at the esophageal side.
Milne et al. [5] formulated criteria for collision tumors
of the gastroesophageal junction: (1) the two components
should show topographical separation; (2) the squamous
component should lie on the esophageal side of the tumor
and the adenocarcinoma component on the gastric side; and
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Table 3: Squamous cell carcinoma and gastric adenocarcinoma collision tumors.
Author Sex/age SCC GA Nodes Follow-up Adjuvant treatment
Wanke [50], 1972 M/52 N/A N/A (−) N/A N/A
Majmudar et al. [7], 1978 M/63 WD N/A GA (+) N/A N/A
Spagnolo and Heenan [51], 1980 M/73 WD MD N/A 2m (DOD) —
M/50 MD MD N/A Not operated
Washizawa et al. [52], 1999 M/68 WD MD SCC/GA (+) 12m (DOD) N/A
Komatsu et al. [27], 2003 M/73 MD WD SCC (+) 19m N/A
Milne et al. [5], 2004 N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A
Santos et al. [53], 2006 M/37 MD MD (−) 11m (DOD) N/A
SCC: Squamous cell carcinoma.
GA: Gastric adenocarcinoma.
WD: Well differentiated.
MD: Moderately differentiated.
m: Months.
DOD: Dead of disease.
N/A: Not available.
Table 4: Gastrointestinal stromal tumor and gastric adenocarcinoma collision tumors.
Author Sex/age GIST GA Nodes Follow-up Adjuvant treatment
Liu et al. [54], 2002 M/70 0/50 hpf AGC, I GA (+) 3m (DOAC) None
Katsoulis et al. [55], 2007 F/78 N/A AGC, PD, D GA (+) N/A N/A
Idema et al. [56], 2008 M/71 <5/50 hpf AGC, D GA (+) N/A N/A
Trabelsi et al. [57], 2008 M/54 0/50 hpf AGC, SRC GA (+) N/A N/A
Bi et al. [58], 2009 F/73 5/50 hpf WD, I GA (+) N/A N/A
Kleist et al. [16], 2010 F/86 <5/50 hpf WD, I (−) 11m N/A
M/78 <5/50 hpf PD, SRC (−) 4m (DOD) N/A
GIST: Gastrointestinal stromal tumor.
GA: Gastric adenocarcinoma.
Hpf: High power field.
AGC: Advanced gastric cancer.
D: Diffuse.
I: Intestinal.
SRC: Signet ring cell.
PD: Poorly differentiated.
m: Months.
DOD: Dead of disease.
DOAC: Dead of another cause.
N/A: Not available.
(3) there should be little or no evidence of intermediate
histologic structure in between.
2.4. Gastrointestinal Stromal Tumors and Gastric Adeno-
carcinoma. Only 7 cases of collision between gastrointesti-
nal stromal tumor and gastric adenocarcinoma have been
described. Four were males and 3 were females. Mean age
was 72 years (54–86). In all these cases, GISTs were of
low malignant potential while gastric adenocarcinoma was
usually advanced.
Kleist et al. [16] described a rare case of a gastric adeno-
carcinoma inside a GIST. They reported that this could have
occurred from dysplastic epithelium trapped inside GIST
sustaining tumorigenic effect of in-tumormicroenvironment
or tumor-to-tumor metastasis from an independent gastric
adenocarcinoma.
2.5. Other Cases. Finally, three unique cases have also been
described in the literature. Dodge [2] in 1961 described a
case of anaplastic carcinoma colliding with gastric adenocar-
cinoma, Adhikari et al. [17] in 2006 described a unique case of
gastric angiosarcoma colliding with GIST, and Go [18] a case
of schwannoma colliding with GIST.
2.6. Tumorigenesis Theories. The cell origin of collision
tumors is obsolete by the time of diagnosis. Theories formu-
lated for their origin, while valuable, are not satisfactory for
all cases.
The oldest and most simplistic theory, adopted by older
reports, is that of accidental meeting of two coexisting
neoplasms developing independently and finally colliding [1,
9, 19, 20]. This theory does not provide any particular expla-
nation of the colliding pattern and makes no differentiation
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between composite and collision neoplasms. Experimental
studies in mice have shown that tumors developing in tumor
environment display a more aggressive behavior, including
infiltration characteristics [19]. This is also the case in rare
tumor-to-tumor metastases cases [6, 19]. This explanation
is challenged by other, modern theories and also by few
studies providing molecular analysis of the tumor elements
of collision tumors [5, 21] that have shown a single cell origin
neoplasm. Still, since synchronous but remote gastric tumors
have been described in approximately 1.25% of all gastric
cancer cases [22], this theory cannot be completely refuted.
Common carcinogen or field theory suggests that a
single carcinogen leads to development of two synchronous,
colliding neoplasms.This theory is appealing for lymphoma-
gastric adenocarcinoma collision tumors, especially since this
carcinogen has probably been isolated. H. pylori is known to
induce both lymphoma and gastric adenocarcinomadevelop-
ment.H. pylori is found in 45–90%of gastric adenocarcinoma
patients and in 56% of lymphoma patients [14]. Suenaga et al.
[23] believe thatH. pylori infection is more common in those
with synchronous lymphoma and gastric adenocarcinoma
than with lymphoma or gastric adenocarcinoma alone.
Gastric adenocarcinoma promotion is probably attrib-
uted to chronic inflammation with cytokines, ammonia, and
proteolytic enzymes involved in the process [6, 24]. Acute
gastritis caused fromH. pylori develops into chronic gastritis,
atrophic gastritis, intestinal metaplasia, dysplasia, and gastric
adenocarcinoma [25]. H. pylori infection also leads to segre-
gation and chronic stimulation of organized lymphoid tissue.
The chronic inflammation of gastric mucosa is dependent
on H. pylori infection and T cell activity. This inflammation
will eventually become autonomous and lead to development
of lymphoma [25]. H. pylori induces MALT lymphoma, the
most common lymphoma element in collision tumors [25,
26]. The majority of synchronous MALT-gastric adenocarci-
noma tumors present H. pylori infection [25].
Another possible carcinogen is Ebstein-Barr Virus (EBV)
[15, 26]. EBV infection is known to induce lymphoma and
possibly has a strong correlationwith gastric adenocarcinoma
development. EBV infection leads to delay in apoptosis
through upregulation of Bcl-2 and p53 and decrease in
cellular differentiation through limited e-cadherin expression
[25]. EBV is encountered in 9–16%of gastric adenocarcinoma
and 9–16% of lymphoma patients [14].
Finally, there are carcinogenic agents inducing develop-
ment of tumors of different histological types in the same
organ. N-methyl-N-nitro-N-nitrosoguanide induces gastric
adenocarcinoma in rats but when combined with agents
altering the mucosal barrier it may lead to leiomyosarcoma
[18].
The common carcinogen theory is appealing due to the
existence of a well-known and established carcinogen, H.
pylori. This theory explains well synchronous tumors and
the predominance of lymphoma-gastric adenocarcinoma
coexistence but does not particularly explain the collision
phenomenon. It also demands different cell origin of the
components at collision neoplasms.
A third hypothesis is the stimulation of tumor-to-tumor
carcinogenesis that is one tumor inducing development of
a second primary. de Leval et al. [11] described a case of col-
lision of a gastrin-producing carcinoid and a gastric adeno-
carcinoma. They stated that gastrin’s trophic effect on gastric
mucosa could induce gastric adenocarcinoma development.
Komatsu et al. [27] described a collision tumor of SCC and
gastric adenocarcinoma of the gastroesophageal junction.
SCC component excreted granulocyte colony stimulating
factor (G-CSF) and presented intense lymphoid infiltration.
Yanagawa et al. [15] believe that immunosuppression induced
by lymphoma could lead to gastric adenocarcinoma develop-
ment. These hypotheses, while interesting, lack experimental
support.
The aforementioned theories assume that collision
tumors originate from two different neoplasms and make
suggestions on their induction and interaction.However clin-
ical and experimental data indicate that at least some collision
tumors arise from a single cell that during tumorigenesis dif-
ferentiates in two distinct histological types.
Milne et al. [5] performed p53 and loss of heterozygosity
(LOH) analysis in two SCC-gastric adenocarcinoma collision
tumors of the gastroesophageal junction. They proved that
they shared the same p53 mutation and the same LOH
pattern. Subsequent comparison of these results with the
same analysis in 3 composite tumors (known to consist of two
divergent lineages originating from a commonprecursor cell)
showed that 2 out of 3 shared the same p53 mutation and all 3
the same LOH pattern. This constitutes strong evidence that
the components of collision tumors originate from the same
cell, which differentiates during tumorigenesis maintaining
a collision pattern. Secondary mutation, affecting cohesion
molecules could be involved but this remains unproven.
Fukui et al. [21] performed the same study on a neuroen-
docrine carcinoma-gastric adenocarcinoma collision tumor
and found the same p53 mutations. Moreover they found
different accumulation of p53 at different tumor components
and additional p53 mutations at distal parts of the tumor.
The tumor studied presented typical histological collision
tumor image and different staining of tumor elements at
immunohistochemistry.
Finally, while most collision tumors present metastases of
one only of their elements, there are reports of lymph node
metastases presenting collision patterns [9, 20]. This could
indicate that metastases occurred before differentiation of
tumor elements yet they differentiated into collision tumors
later.
Tumorigenesis of neuroendocrine carcinoma-gastric
adenocarcinoma collision tumors can be investigated in a
different light. A number of neuroendocrine cells are often
present inside gastric adenocarcinomas [28] while neuroen-
docrine carcinomas are often accompanied by gastric adeno-
carcinomas in other parts of gastrointestinal track [21]. It has
been estimated that a neuroendocrine tumor can coexist with
gastric adenocarcinoma in 0.4–4.3% of all cases [29]. Close
association of these tumor types has created the concept
of Mixed Endocrine Exocrine Carcinomas (MEECs) [30].
They are neoplasms with divergent exocrine and endocrine
differentiationwith origin in appendix, pancreas, or stomach.
For a neoplasm to be characterized as MEEC, it should have
at least 30% participation of an endocrine component,
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although this limit is arbitrary [31]. A common genetic origin
of cell components in these neoplasms has been suggested
[27, 28]. It is noteworthy that Furlan et al. [32], while
studying clonality of a rectal endocrine-exocrine collision
tumor, found different origins of the tumor components.
MEECs in the stomach are relatively rare; they are more
common in the pancreas and appendix [33].
In the literature these neoplasms are often called by
different names: composite glandular-endocrine carcinoma,
collision tumor, neuroendocrine differentiated gastric adeno-
carcinoma, amphicrine tumor, and goblet cell carcinoid [33].
MEECs can be categorized into four categories according to
their morphological features: carcinomas with interspersed
endocrine cells, carcinoids with interspersed nonendocrine
cells, amphicrine tumors, and mixed tumors [34]. Mixed
tumors can be classified into composite tumors, where
histological components are distinct but admixed and present
areas of histological transition and collision tumors, where
histological components are not admixed and present a
clear-cut margin between them [11, 21, 35].
Collision tumors between a neuroendocrine (carcinoid)
neoplasm and a gastric adenocarcinoma could represent an
extreme form of a well-known and described entity, thus
placing collision tumor in the context of a larger group.
This theory also enhances the origin of collision tumor
from a single cell and is compatible with experimental data.
Its disadvantage is that, while supported by genetic studies
in neuroendocrine carcinoma-gastric adenocarcinoma and
SCC-gastric adenocarcinoma collision tumors, no such data
exist for other collision tumor types.
2.7. Clinical, Diagnostic, and Therapeutic Implications. As
most of the data on collision tumors come from articles
with predominately histopathologic interest, relevant clinical
information is scarce.
Amale predominance in collision tumors has been noted
by many authors [14, 36] and is confirmed in this report
(46 males and 16 female patients) as is a predominance in
the 5th and 6th decade of life. A male predominance has
also been noted in synchronous lymphoma and gastric ade-
nocarcinoma patients [25].
Collision tumors are preoperatively indistinguishable
from their predominant tumor type and present no dif-
ferences in terms of clinical and radiological image. Their
presenting symptoms are nonspecific and include abdominal
pain, loss of appetite, haematemesis, melaena, and weight
loss. Additional findings relevant to tumor type are rarely
present. Yoshino et al. and de Leval et al. diagnosed such
a tumor from high gastrin levels, while Komatsu et al.
suspected such a tumor from high G-SF production [11, 27,
37]. Apart from these 2 reports no other specific findings have
been described elsewhere. No specific tumor marker rise has
been identified either. Finally, abdominal CT and upper GI
endoscopy have not been helpful in the detection in the dual
nature of the lesion under investigation.
The vast majority of them are diagnosed postoperatively,
during histologic examination of gastrectomy specimens.
Only rarely they are diagnosed preoperatively [3, 24, 37, 38]
with only 2 possible scenarios: either presence of two tumor
types in the same sample or different tumor types in two
different biopsies.This underlines the importance of multiple
tumor biopsy sites.
Data on patient’s survival or postoperative therapy are
lacking and therefore no meaningful analysis can be per-
formed. In collision lymphoma and gastric adenocarcinoma
tumors, prognosis follows that of gastric adenocarcinoma
[14]. Most authors believe that the same is true for all
collision-type tumors [5, 39, 40]. However, it should be
noted that most of these tumors are diagnosed late during
their natural course and thus their dismal prognosis might
be independent from their particular histological image or
collision elements.
It is rational to suggest that surgery remains the cor-
nerstone of the treatment of all resectable nonlymphoma
tumors. Adjuvant therapy should target the more advanced
or aggressive tumor type [40, 41]. The issue of collision
elements being staged independently and treated with sep-
arate adjuvant treatment has been discussed [22] but solid
evidence is missing. Neoadjuvant treatment has not, to
the best of our knowledge, been applied yet either. The
issue of individualizing treatment is obviously important
in patients with collision tumors, as surgery and systemic
treatment must be tailored to meet each patient’s needs.
These needs may be difficult to define as the two components
are at different stage of progress, have different malignant
capacity, and respond differently to surgery, radiotherapy, or
chemotherapy.The role of themultidisciplinarymanagement
is therefore critically important.
3. Conclusions
Collision tumors are rare neoplasms consisting of two
different histologic patterns and a clear margin with no
intermingling. Although rarity of these cases and lack of
relevant data preclude detailed investigation, they seem
aggressive neoplasms with dismal prognosis. Their origin
is obsolete by the time of diagnosis but few available data
indicate a single cell origin differentiating into two different
histological patterns during tumorigenesis yet maintaining
the unique collision pattern between them.Their relationship
with composite and amphicrine tumors is not clear but they
share common characteristics. Clinically they are usually
indistinguishable from the dominant tumor type and diagno-
sis is almost always set postoperatively on histology. Despite
their rarity, their unique characteristics could shed light on
many aspects of tumorigenesis including differentiation and
adhesion. Surgeons and pathologists should be aware of those
rare entities and when encountered should be submitted to
proper histologic and molecular analysis.
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